The absence of effective small animal models has significantly hampered efforts to develop curative treatments for the nearly 300 million people living with chronic hepatitis B infection. This limitation stems from the virus's extraordinary selectivity, naturally infecting only human and chimpanzee liver cells while completely resisting replication in standard laboratory mice.
Using an innovative transposon delivery system, investigators bypassed the normal viral entry pathway and directly introduced hepatitis B genetic material into mouse liver cells. This approach revealed that once inside, mouse cells performed all the complex molecular machinery required for viral persistence with remarkable efficiency. The cells successfully formed covalently closed circular DNA, the persistent viral reservoir that makes hepatitis B so difficult to cure, at levels matching human cells. Critical processes including viral nucleocapsid uncoating and nuclear DNA import proceeded normally across multiple mouse genetic backgrounds.
This discovery fundamentally reframes our understanding of species barriers in hepatitis B infection. The restriction appears concentrated at viral entry rather than in the sophisticated intracellular replication machinery, as previously assumed. Since mouse cells expressing human entry receptors can support hepatitis D virus infection, which shares early entry mechanisms with hepatitis B, the data points to a specific late-stage entry block unique to hepatitis B.
These findings represent more than incremental progress in virology. By identifying that the primary obstacle lies in viral entry mechanisms rather than fundamental cellular incompatibility, this work opens new avenues for engineering mouse models that could accelerate therapeutic development for one of the world's most persistent viral infections.